Key facts
- It has raised $90.9M; the latest was Later Stage VC ($28.7M) in Feb 2026.
- Notable investors include Lapam Capital, Tailong VC, South China Venture Capital, Hangzhou Hi-Tech Financial Investment Group, Huayi Capital — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for iMBIORAY
- ·The full record, as it builds
Funding rounds
No funding rounds for iMBIORAY are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iMBIORAY
Developer of innovative drugs intended for the treatment of tumors and immune diseases. The company offers research and clinical development programs focused on off-the-shelf natural killer cell therapies, with a drug focus on technology in non-genetically modified CAR-NK (Chimeric antigen receptor-NK) and Bispecific monoclonal antibody, providing enabling oncology and immunology clinicians, research hospitals, and biopharma cancer patients with advanced and targeted treatment.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2014
- Website
- imbioray.com/
- Ownership
- Privately Held (backing)
iMBIORAY doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iMBIORAY shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iMBIORAY in its N-PORT filings yet. We sweep new filings monthly.